It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...

Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

New York, New York-- (Newsfile Corp. - September 18, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18 ...

Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.